Hemispherx BioPharma, Inc. Press Releases

HEB 
$0.243
*  
0.01
4.29%
Get HEB Alerts
*Delayed - data as of Feb. 27, 2015  -  Find a broker to begin trading HEB now
Exchange: AMEX
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Hemispherx Biopharma: Institute of Medicine, the Health Arm of the US National Academy of Sciences Reframes Chronic Fatigue Syndrome (CFS) as a "Systemic Exertion Intolerance Disease" (SEID)
2/23/2015 8:30:00 AM - GlobeNewswire


Hemispherx Biopharma and USAMRIID to Present New Discoveries Concerning the Efficacy of Ampligen(R) Against the Ebola Virus at Upcoming International Symposium on Filoviruses
2/12/2015 8:30:00 AM - GlobeNewswire


Hemispherx Biopharma Posts USAMRIID Ebola Study Concluding Ampligen(R) Produced 100% Survival Rate in Rodents With 100% Mortality in Placebo
2/9/2015 8:30:00 AM - GlobeNewswire


Hemispherx: U.S. Army Scientists (USAMRIID) Find Ampligen(R) Produces 100% Survival Rate in Ebola Virus Rodent Study
2/2/2015 8:30:00 AM - GlobeNewswire


USAMRIID Reports Genetic Changes in Ebola Virus May Impede Potential Treatments
1/26/2015 8:30:00 AM - GlobeNewswire


Hemispherx Biopharma Awarded $770,852 by Federal Judge
1/15/2015 8:30:00 AM - GlobeNewswire


Low Natural Killer (NK) Activity Observed Across the Chronic Fatigue Syndrome (CFS) Disease Spectrum
1/12/2015 8:30:00 AM - GlobeNewswire


Arrowhead Issues Diligence and Valuation Report on Hemispherx Biopharma
1/9/2015 8:30:00 AM - GlobeNewswire


Hemispherx's Ampligen(R) Provides Anti-Tumor Activity Analogous to Emerging Immune Checkpoint Inhibitors
12/16/2014 8:30:00 AM - GlobeNewswire


Hemispherx Announces Data Showing Inhibition of Ebola by Ampligen(R) Enlarged by Howard University Research
12/9/2014 9:51:00 AM - GlobeNewswire